
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc. has seen a remarkable share price appreciation of nearly 90% in the last month, indicative of growing investor confidence. The company's robust potential is highlighted by its proprietary Total Addressable Market (TAM) analysis, forecasting a multi-billion dollar opportunity in the US and UK, alongside strategic partnerships aimed at capitalizing on this market. Furthermore, with over $400 million pending to enhance the company's balance sheet, GRAIL is well-positioned to navigate regulatory uncertainties while continuing to advance its leading multi-cancer early detection technology.
Bears say
GRAIL Inc has experienced continuous net losses since its inception and anticipates further losses as it pursues regulatory approvals and maintains its operational infrastructure. The company faces significant challenges, including potential legislative delays affecting reimbursement for its multi-cancer early detection test, as well as competitive pressures from larger diagnostic firms with established market presence. Additionally, GRAIL's projected selling prices have been lowered, and there are concerns regarding elevated selling, general, and administrative expenses, which could hinder its commercialization efforts and overall financial stability.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares